J A Meyerhardt

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1702-11. 2012
  2. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
  3. pmc Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:608-15. 2012
  4. pmc Energetics in colorectal and prostate cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:4066-73. 2010
  5. ncbi request reprint Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8453-60. 2005
  6. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
  7. ncbi request reprint Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 298:754-64. 2007
  8. ncbi request reprint Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
  9. ncbi request reprint Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
    Jeffrey A Meyerhardt
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3535-41. 2006
  10. ncbi request reprint Physical activity and survival after colorectal cancer diagnosis
    Jeffrey A Meyerhardt
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3527-34. 2006

Detail Information

Publications77

  1. pmc Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1702-11. 2012
    ..The influence of glycemic load and related measures on survival among colon cancer patients remains largely unknown...
  2. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
    ..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
  3. pmc Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:608-15. 2012
    ..Clinical trials have shown that adding bevacizumab to cytotoxic chemotherapy improves survival for patients with colorectal cancer, although its effectiveness in the Medicare population is uncertain...
  4. pmc Energetics in colorectal and prostate cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:4066-73. 2010
    ..This article will evaluate the emerging data on energy balance in patients with colorectal or prostate cancer...
  5. ncbi request reprint Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8453-60. 2005
    ..Although several comprehensive dietary questionnaires have been validated and calibrated in healthy populations, similar studies have not been performed among cancer patients...
  6. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  7. ncbi request reprint Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 298:754-64. 2007
    ..Dietary factors have been associated with the risk of developing colon cancer but the influence of diet on patients with established disease is unknown...
  8. ncbi request reprint Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
    ....
  9. ncbi request reprint Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
    Jeffrey A Meyerhardt
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3535-41. 2006
    ..Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown...
  10. ncbi request reprint Physical activity and survival after colorectal cancer diagnosis
    Jeffrey A Meyerhardt
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3527-34. 2006
    ..Physically active individuals have a lower risk of developing colorectal cancer but the influence of exercise on cancer survival is unknown...
  11. pmc Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 38:533-41. 2011
    ..The data supporting these observations will be reviewed, potential mechanisms of actions will be discussed, and the next steps forward will be proposed...
  12. ncbi request reprint Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  13. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..Whether these results apply to other cancer types is unknown but worthy of further study...
  14. ncbi request reprint Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1402-10. 2005
    ..The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer...
  15. ncbi request reprint Impact of diabetes mellitus on outcomes in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:433-40. 2003
    ..To determine the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity among patients with curatively resected colon cancer...
  16. pmc Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:4109-15. 2008
    ..However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied...
  17. ncbi request reprint Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:484-95. 2003
    ..Obesity is a risk factor for the development of colon carcinoma. The influence of body mass index (BMI) on long-term outcomes and treatment-related toxicity in patients with colon carcinoma has not been well characterized...
  18. pmc Interaction of molecular markers and physical activity on mortality in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5931-6. 2009
    ..Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival. Whether molecular features of the tumor portend more or less likelihood for benefit from exercise is unknown...
  19. ncbi request reprint Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:166-74. 2004
    ..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
  20. ncbi request reprint Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:648-57. 2004
    ..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer...
  21. ncbi request reprint Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 22:1439-46. 2004
    ..To examine the predictive value of baseline serum bilirubin measurement for chemotherapy-related toxicity or efficacy among patients receiving irinotecan for metastatic colorectal cancer...
  22. ncbi request reprint Epidermal growth factor receptor inhibitors and colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham and Women s Hospital Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 18:35-8. 2004
    ..The role of other targeted agents against EGFR, including other monoclonal antibodies as well as inhibitors of the intracellular tyrosine kinase domain, will also be discussed...
  23. ncbi request reprint Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer
    J A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 18:1185-9. 2007
    ..Targeting the epidermal growth factor receptor and angiogenesis have proven useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of both pathways is unknown...
  24. ncbi request reprint Adjuvant treatment of colorectal cancer
    Brian M Wolpin
    Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    CA Cancer J Clin 57:168-85. 2007
    ..Current randomized clinical trials in the adjuvant therapy of colorectal cancer are examining the value of adding agents known to be active in metastatic disease, including those that modify specific molecular targets...
  25. ncbi request reprint Adjuvant therapy in gastric cancer: can we prevent recurrences?
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Channing Laboratory, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Oncology (Williston Park) 17:714-21, 728; discussion 728-9, 732-3. 2003
    ..We focus attention on the recent widespread acceptance of adjuvant chemoradiotherapy, based on the results of Intergroup trial 0116. Future strategies incorporating different modalities of treatment will be outlined...
  26. pmc A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
    J A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1367-73. 2011
    ..We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma...
  27. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....
  28. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  29. ncbi request reprint Chemotherapy options for gastric cancer
    Jeffrey A Meyerhardt
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Radiat Oncol 12:176-86. 2002
    ..As a greater understanding of the molecular basis of gastric cancer is gained, the inclusion of biologic-based therapies will hopefully advance our ability to treat patients with gastric cancer more effectively...
  30. ncbi request reprint Systemic therapy for colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 352:476-87. 2005
  31. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  32. pmc Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
    P C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 20:475-80. 2009
    ..Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer...
  33. ncbi request reprint Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 139:649-57. 2003
    ..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
  34. ncbi request reprint Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:6650-6. 2005
    ..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib...
  35. pmc Aspirin dose and duration of use and risk of colorectal cancer in men
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    Gastroenterology 134:21-8. 2008
    ..Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited...
  36. ncbi request reprint Follow-up strategies after curative resection of colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Semin Oncol 30:349-60. 2003
    ..Further research designing appropriate postoperative testing is needed to guide physicians and patients after the curative resection of a colorectal cancer...
  37. pmc Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4665-73. 2009
    ....
  38. pmc Cohort study of fatty acid synthase expression and patient survival in colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:5713-20. 2008
    ..Fatty acid synthase (FASN) is physiologically regulated by energy balance and is often upregulated in colorectal cancer. Nonetheless, the influence of FASN expression on patient outcome is uncertain...
  39. pmc A cohort study of p27 localization in colon cancer, body mass index, and patient survival
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital, Boston, and Harvard Medical School 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1849-58. 2009
    ..08). In conclusion, p27 alterations in colon cancer are associated with superior prognosis. Adverse prognostic effect of obesity seems limited to patients with nuclear p27 expression, suggesting a host-tumor interaction...
  40. pmc Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer
    Y Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Room JF 215C, Boston, MA 02115, USA
    Br J Cancer 103:1025-33. 2010
    ..AMP-activated protein kinase activation is cytotoxic to cancer cells, supporting AMPK as a tumour suppressor and a potential therapeutic target. However, no study has examined its prognostic role in colorectal cancers...
  41. pmc Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?
    Andrea P Myers
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 15:6748-50. 2009
    ..The ability to select patients with the highest risk of recurrence and greatest therapeutic response will improve rectal cancer care...
  42. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....
  43. pmc KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7322-9. 2009
    ....
  44. pmc Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1599-606. 2011
    ....
  45. ncbi request reprint New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient
    Nadine Jackson McCleary
    Department of Medical Oncology, Gastrointestinal Cancer Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 24:3-8. 2010
    ..We will discuss factors to consider in assessing the risk of recurrence in stage II disease. We will also outline considerations regarding adjuvant therapy in older patients...
  46. pmc p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2513-21. 2009
    ..Patient BMI also differentially influences prognosis according to p21 CDKN1A status. Our data suggest host-tumor interactions influencing tumor aggressiveness...
  47. pmc Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:4354-63. 2010
    ..Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown...
  48. pmc Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803
    Nadine Jackson McCleary
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02113, USA
    Cancer 116:957-66. 2010
    ..Cigarette smoking has been shown to increase the risk of developing colorectal cancer, particularly smoking early in life. Little is known about the impact of tobacco use on colon cancer recurrence among colon cancer survivors...
  49. pmc Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:8263-9. 2008
    ..We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer...
  50. doi request reprint CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Mod Pathol 21:245-55. 2008
    ..Our data may provide supporting evidence for a difference in pathogenesis of DNA methylation between CIMP-low and CIMP-high tumors...
  51. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
    ..However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain...
  52. ncbi request reprint Adjuvant and neoadjuvant approaches in gastric cancer
    Kimmie Ng
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer J 13:168-74. 2007
    ....
  53. doi request reprint Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer
    Kimmie Ng
    Division of Medical Oncology, Dana Farber Cancer Institute Boston, MA 02115, USA
    J Clin Oncol 26:2984-91. 2008
    ..Higher plasma 25-hydroxyvitamin D(3) (25(OH)D) levels are associated with a decreased incidence of colorectal cancer, but the influence of plasma 25(OH)D on the outcome of patients with established colorectal cancer is unknown...
  54. doi request reprint Prediagnostic plasma folate and the risk of death in patients with colorectal cancer
    Brian M Wolpin
    Department of MedicalOncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 26:3222-8. 2008
    ..Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer...
  55. ncbi request reprint Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer 110:581-9. 2007
    ..A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC...
  56. ncbi request reprint Hormone replacement therapy and survival after colorectal cancer diagnosis
    Jennifer A Chan
    Dana Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA
    J Clin Oncol 24:5680-6. 2006
    ..Postmenopausal estrogen use has been shown to decrease the incidence of colorectal cancer, but there is limited information regarding the effect of estrogen use on survival after diagnosis of colorectal cancer...
  57. ncbi request reprint Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  58. doi request reprint DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor
    Lynn Kristin Bracht
    Center for Neuro Oncology, Boston, MA, USA
    J Clin Oncol 26:4843-4. 2008
  59. pmc Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
    JAMA 294:914-23. 2005
    ..However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited...
  60. pmc Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:193-8. 2009
    ..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine...
  61. pmc Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:176-85. 2009
    ..Excess energy balance leads to increased circulating insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, which promote cancer cell growth in preclinical models...
  62. doi request reprint Family history and survival after colorectal cancer diagnosis
    Adam J Bass
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 112:1222-9. 2008
    ..The influence of a family history of colorectal cancer on survival after a diagnosis of colorectal cancer was examined in a large cohort of women...
  63. doi request reprint A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
    J R Strosberg
    Department of GI Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Endocr Relat Cancer 20:383-90. 2013
    ..Although well tolerated, treatment with single-agent ganitumab failed to result in significant tumor responses among patients with metastatic well-differentiated carcinoid or pNET...
  64. pmc A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 137:1609-20.e1-3. 2009
    ..Synchronous colon cancers have not been compared with control solitary cancers in a prospective study...
  65. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  66. pmc Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer
    Shoko Kure
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009
    ..Our data support potential interactions between the VDR, RAS-MAPK and PI3K-AKT pathways, and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR...
  67. pmc Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
    K Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 101:916-23. 2009
    ....
  68. pmc Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Gastroenterol 105:420-33. 2010
    ....
  69. pmc A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
    Clin Cancer Res 15:4431-8. 2009
    ....
  70. pmc O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:338-45. 2009
    ..We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens...
  71. pmc HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Am J Pathol 176:2292-301. 2010
    ..039). In conclusion, HIF1A expression is independently associated with poor prognosis in colorectal cancer, suggesting HIF1A as a biomarker with potentially important therapeutic implications...
  72. ncbi request reprint MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Carcinogenesis 28:1985-90. 2007
    ..56C>T) of the MGMT promoter and promoter methylation/silencing of MGMT in colorectal cancer. Our data provide compelling evidence for common susceptibility for MGMT promoter CpG island methylation...
  73. pmc Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:4591-8. 2009
    ..However, it is unclear whether 18q LOH in colorectal cancer has any prognostic implication independent of MSI status and other potential predictors of clinical outcome...
  74. pmc Impact of hospital volume on recurrence and survival after surgery for gastric cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Surg 245:426-34. 2007
    ..However, because such data may be significantly influenced by the impact of postoperative mortality, and may be imbalanced for factors important to survival, the true nature of this relationship remains uncertain...
  75. pmc Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 75 Francis St, BWH Pathology, Boston, MA 02115, USA
    Gut 56:1564-71. 2007
    ..O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and silencing have been associated with G>A mutations and microsatellite instability-low (MSI-low)...
  76. ncbi request reprint Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 19:59-68. 2006
    ..Signet ring cell carcinoma and mucinous carcinoma are related subtypes of colorectal adenocarcinoma, but have molecular features distinct from each other...
  77. pmc Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 9:569-77. 2007
    ..Cytoplasmic beta-catenin is associated with COX-2 overexpression, supporting the role of cytoplasmic beta-catenin in stabilizing PTGS2 (COX-2) mRNA...